U.S. Markets closed

Achieve Life Sciences, Inc. (ACHV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.72-0.36 (-3.25%)
At close: 4:00PM EDT

12.90 +2.18 (20.34%)
After hours: 6:43PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.08
Open11.09
Bid9.90 x 1100
Ask12.88 x 1200
Day's Range10.63 - 11.25
52 Week Range6.20 - 18.26
Volume75,163
Avg. Volume297,316
Market Cap65.927M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-5.42
Earnings DateMay 12, 2021 - May 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.20
  • Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) (varenicline) in Addiction
    ACCESSWIRE

    Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) (varenicline) in Addiction

    Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 25, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced online publication of the results from the Phase 3 RAUORA trial in the scientific journal Addiction.

  • ACHV: Fourth Quarter and Full Year 2020 Results
    Zacks Small Cap Research

    ACHV: Fourth Quarter and Full Year 2020 Results

    By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Fourth Quarter and Fiscal Year 2020 Results Achieve Life Sciences, Inc. (NASDAQ: ACHV) reported fourth quarter and fiscal year 2020 results in a press release and conference call held after market close on March 12, 2021.  The company concurrently filed its 10-K with the SEC.  Highlights from 2020 include the

  • Achieve Life Sciences to Participate in M-Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
    ACCESSWIRE

    Achieve Life Sciences to Participate in M-Vest and Maxim Group Inaugural Emerging Growth Virtual Conference

    Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 16, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Achieve's Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M-Vest and Maxim Group.